Clinical equipoise & the RCT dilemma

Slides:



Advertisements
Similar presentations
Scientific Validity Hemantha Senanayake, Chairman, Ethics Review Committee, Faculty of Medicine, University of Colombo.
Advertisements

Informed Choice. Overview Brief introduction to cases (ours, yours) Elements of informed choice Capacity Informed choice for research Return to cases.
Phase O Trials: Ethical Considerations Holly Taylor, PhD, MPH Department of Health Policy and Management Bloomberg School of Public Health Berman Institute.
Introduction to medical ethics Dr Leena Al-Qasem.
Chapter 3 Flashcards. obligation of an individual to other individuals based on a social or legal contract to justify his or her actions; the processes.
Recruitment to Trials. Background Recruitment of participants is a VERY important issue. The general consensus is that most trials under recuit.
EPECEPECEPECEPEC EPECEPECEPECEPEC Advance Care Planning Advance Care Planning Module 1 The Project to Educate Physicians on End-of-life Care Supported.
Obtaining Informed Consent: 1. Elements Of Informed Consent 2. Essential Information For Prospective Participants 3. Obligation for investigators.
Subject Selection and Recruitment David Wendler Department of Clinical Bioethics NIH, USA.
Clinical Trials Hanyan Yang
بسم الله الرحمن الرحيم. THE TITLE “INTRODUCTION”
Journal Club Alcohol and Health: Current Evidence January–February 2007.
1Carl-Fredrik Burman, 11 Nov 2008 RSS / MRC / NIHR HTA Futility Meeting Futility stopping Carl-Fredrik Burman, PhD Statistical Science Director AstraZeneca.
Sample Size Determination
MEDICAL RESEARCH AND CLINICAL TRIALS Rels 300 / Nurs October 2014.
Equipoise and the ethics of clinical research l When is it ethical to initiate a randomized- controlled trial? Freedman, NEJM, l “There exists (or.
Study Designs By Az and Omar.
From Informed Consent to Enlightened Decision-Making From Informed Consent to Enlightened Decision-Making Jerry Menikoff.
Are sham operations and placebos justifiable in research? Leslie J. Kohman, MD SUNY Upstate Medical University Syracuse, NY Cardiothoracic Ethics Forum:
Long-Term Effects of Continuing Adjuvant Tamoxifen to 10 Years versus Stopping at 5 Years After Diagnosis of Oestrogen Receptor- Positive Breast Cancer:
Ethical Issues in Clinical Trials in Developing Countries Carl H. Coleman Professor of Law Director, Health Law & Policy Program Seton Hall Law School.
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
Intervention Studies Principles of Epidemiology Lecture 10 Dona Schneider, PhD, MPH, FACE.
Evidence Based Practice
Medical Ethics By Shauna O’Sullivan.
European Society of Cardiology Cardiovascular diseases in women.
Julio A. Ramirez, MD, FACP Professor of Medicine Chief, Infectious Diseases Division, University of Louisville Chief, Infectious Diseases Section, Veterans.
PALLIATIVE CARE INFORMATION ACT Webinar Tuesday, April 12, 2011 Presented by: Laurie T. Cohen, Esq. Wilson, Elser, Moskowitz, Edelman & Dicker LLP 677.
Challenges of Non-Inferiority Trial Designs R. Sridhara, Ph.D.
1 Ethical issues in clinical trials Bernard Lo, M.D. February 10, 2010.
BIG 1-98/IBCSG Henning Mouridsen for the BIG 1-98 Collaborative Group Authors: Sunil Verma Date posted: December 22, 2008.
Statistical Topic: Ethics and Trial Design* Elizabeth Garrett-Mayer August 14, 2009 HCC Journal Club * Thanks to my colleague Steve Goodman.
Good Research, Bad Choices? Mary Coombs. What Makes Something Research Rather Than Treatment?
Experimental studies Jean-François Boivin 25 October 2010.
I.T. Gangaidzo MA, BM BCh(Oxon); DTM&H(Lond); FRCP(Lond)
How to Analyze Therapy in the Medical Literature (part 1) Akbar Soltani. MD.MSc Tehran University of Medical Sciences (TUMS) Shariati Hospital
Consent Procedures. What is Informed Consent? Consent by a patient to a surgical or medical procedure or participation in a clinical study after achieving.
Hayat Mushcab, B.Sc. M.Sc. W. George Kernohan, PhD Jonathan Wallace B.A., M.Sc. Roy Harper, M.D, and Suzanne Martin, PhD THE JOURNEY TOWARDS SUCCESSFUL.
Ethical issues in selection of research subjects Bernard Lo, M.D. July 28, 2001.
Research Issues Can be both sociological and ethical Excesses in the past have made rules and standards necessary Rules are participant oriented and protective.
1 Ethical Concerns in Pediatric Placebo-controlled Trials from the European Experience Ethics of Placebo-controlled Trials in Children FDA Pediatric Advisory.
Presentations in this series 1.Overview and Randomization 2.Self-matching 3.Proxies 4.Intermediates 5.Instruments 6.Equipoise Avoiding Bias Due to Unmeasured.
Copyright, 1996 © Dale Carnegie & Associates, Inc. CLINICAL TRIALS AND HUMAN SUBJECT PROTECTION: A PLAINTIFF’S PERSPECTIVE ALAN MILSTEIN SHERMAN SILVERSTEIN.
Randomised and Controlled Trials The Unofficial Guide by Goadsby&Gould.
Medical Research and Clinical Trials Rels 300 / Nurs October 2015.
Basics of Research Ethics Prepared by: R. Bortolussi MD FRCPC Professor Pediatrics Dalhousie University Workshop Google images.
ETHICAL ISSUES AND INFORMED CONSENT Juan M. Lozano, MD, MSc Department of Paediatrics and Clinical Epidemiology Unit School of Medicine, Javeriana University.
LEGAL ASPECTS IN LAW FOR PATIENT EDUCATION Dr Ghiyasvandian Assistant Professor Member of Medical-Surgical Nursing Department School of Nursing and Midwifery.
Copyright © 2008 Delmar Learning. All rights reserved. Unit 3 Consumer Rights and Responsibilities in Health Care.
Research Design Evidence Based Medicine Concepts and Glossary.
European Patients’ Academy on Therapeutic Innovation Ethical and practical challenges of organising clinical trials in small populations.
Ethics in Health Care. SCOPE OF PRACTICE Duties and responsibilities a health care professional can perform based upon:
Ebola, study design, and Ethics Nancy E. Kass, ScD Berman Institute of Bioethics and Bloomberg School of Public Health.
Date of download: 5/31/2016 From: Medications for Risk Reduction of Primary Breast Cancer in Women: U.S. Preventive Services Task Force Recommendation.
Clinical equipoise and RCT design Charles Weijer, MD, PhD.
J Clin Oncol 30: R2 윤경한 / Prof. 김시영 Huan Jin, Dongsheng Tu, Naiqing Zhao, Lois E. Shepherd, and Paul E. Goss.
MA.17R: Reduced Risk of Recurrence With Extending Adjuvant Letrozole Beyond 5 Yrs in Postmenopausal Women With Early-Stage Breast Cancer CCO Independent.
Analytical Interventional Studies
Week 5: Ethical, Legal & Social Issues in Applied Genomics
PRINCIPLES OF ETHICS IN MEDICINE ETHICS IN MEDICINE ETM: 400 GROUP 1
Randomized Trials: A Brief Overview
From: Medications for Risk Reduction of Primary Breast Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement Ann Intern Med. 2013;159(10):
EMPHASIS-HF Extended Follow-up
Informed Consent to Treatment
Equipoise ”Balance of forces or interests”
Liability for failure to disclose and the challenge of precision medicine Colm McGrath Faculty of Law.
ABSTRACT ABCSG 6a MA17-1 MA.17R NSABP B-33. Extended Adjuvant Therapy With Aromatase Inhibitor Among Postmenopausal Breast Cancer.
ONCOLOGYEDUCATION.COM ARTICLE SUMMARIES
The Research Question Background: Question:
Ethical Theories and Principles in Clinical and Research
Presentation transcript:

Clinical equipoise & the RCT dilemma Gopal Sreenivasan Crown Professor of Ethics Duke University

summary problem: RCT permissible? standard solution: equipoise example

clinical trials is it permissible to do medical research with human beings? isn’t medical research basically just better, fancier clinical care? no, they are fundamentally different

research vs. clinical care they have fundamentally different aims medical research: to produce generalisable medical knowledge clinical care: to secure the best (health) interests of the patient

research vs. clinical care their different aims appear to be in conflict, i.e. aims of clinical research appear inconsistent with the best health interests of the individual moreover, this is inherent in the nature of medical research

apparent conflict best seen as between investigator’s scientific duty to produce valid general knowledge investigator’s clinical duty to advance best health interests of individual subject

apparent conflict arises because RCT enrolment seems inconsistent with subject’s best health interests because of presumed inferiority of unproven experimental arm which ‘half’ the subjects will get

how to resolve? which obligation should prevail in this conflict? isn’t it obviously the obligation of the person as physician? are not the interests of the individual sacrosanct?

how to resolve? should not the obligation of the person as physician prevail? if the conflict is inherent in the nature of medical research, this entails not doing any research but medical practice depends on (past) research

conundrum? indeed, the physician’s own obligation later to provide the best care to patients (in the future) depends on research now conflict is between present and future patients

equipoise appearance of conflict depends on the inference not known not to be effective therefore, not effective but perhaps this is a mistake

equipoise ‘equipoise’ exists between two treatments, A and B, when there is ‘a state of genuine uncertainty regarding the comparative merits’ of A and B Benjamin Freedman

equipoise if the investigator is in a state of equipoise between the experimental arm and the control arm of an RCT then she does not violate her obligation as physician for she does not knowingly offer inferior treatment to the subject

clinical equipoise requires existence of honest professional disagreement in expert community about which of trial’s two arms is clinically superior [assuming that ] one ≈ standard of care

solution RCT permissible when there is clinical equipoise regarding the two arms at the beginning of the trial trial is designed to make it reasonable to expect that successful results will disturb this equipoise

solution if investigator has a preference, why does this not violate her obligation as physician? because the standards of professional responsibility are social in nature Freedman’s official answer

solution but plausibility of this also implicitly relies on fact that medical community has a high(er) standard of evidence indeed, a ‘gold’ standard: RCT! that is why clinical equipoise is robust: disturbed only by RCT

example consider 2003 study of letrozole after tamoxifen for breast cancer result announced in PE Goss et alia, NEJM (2003) 349: 1793-1802.

2003 example news items concerned fact that the study was interrupted mid-course preliminary analysis confirmed significant benefit from experimental intervention

yay! to wit, a 43 percent reduction in risk of a recurrence or of new contralateral breast cancer study was stopped and placebo group was allowed to cross-over

but study was stopped after 2.4 years primary aim of the study was therefore not realised to study 5 year effect

oh therefore cannot document a ‘survival’ advantage defined in terms of 5 years recommendation for 5 (or indeed > 2.4) year treatment data do not support

uh oh? stopping decision ‘undeniably diminishes the clinical usefulness of the data’ Bryant and Wolmark accompanying NEJM editorial

thank you